文献速递垂体与肾上腺疾病糖尿病

FOXA2基因缺陷导致胰腺与垂体发育不良及功能障碍

Dysgenesis and Dysfunction of the Pancreas and Pituitary Due to FOXA2 Gene Defects.
PubMed 文献 · J Clin Endocrinol Metab · 2021-01-01

本文报道2例FOXA2基因缺陷导致的综合征性垂体功能减退患者:一例为新型杂合无义变异c.616C>T(p.Q206X),导致FOXA2 DNA结合域部分缺失,转录激活功能受损,该患者为文献中第6例FOXA2突变患者,也是首例表现为胰腺发育不良的患者;另一例为新发20p11.2微缺失(8.53 Mb),涵盖FOXA2基因,该患者发生糖尿病,对磺脲类治疗有效。结论认为这2例拓宽了FOXA2相关疾病的分子与临床谱,首次报道无义突变及胰腺发育不良病例。

要点

  • FOXA2缺陷可导致综合征性垂体功能减退,并伴胰腺发育不良或功能障碍。
  • 新型无义变异p.Q206X导致FOXA2 DNA结合域部分缺失,转录激活功能受损。
  • FOXA2缺失患者可发生糖尿病,且对磺脲类治疗有效。

核心结论

  • FOXA2基因缺陷可导致胰腺与垂体发育不良及功能障碍,本文报道首例FOXA2无义突变及首例胰腺发育不良病例。

研究设计与样本

  • 病例报告:2例FOXA2基因缺陷相关的综合征性垂体功能减退患者,结合分子遗传学与功能实验进行特征分析。

主要发现

  • 患者1携带新型杂合无义变异c.616C>T(p.Q206X),导致FOXA2 DNA结合域部分缺失,GLUT2-luciferase报告基因转录激活受损,为文献中第6例FOXA2突变患者及首例胰腺发育不良患者。
  • 患者2携带新发20p11.2微缺失(8.53 Mb),涵盖FOXA2基因,发生糖尿病且对磺脲类治疗有效。

临床怎么用

  • 对综合征性垂体功能减退患者,尤其伴胰腺发育异常或糖尿病者,应考虑FOXA2基因检测。
  • FOXA2缺陷相关糖尿病可能对磺脲类治疗有效,可作为个体化治疗选择。

局限性

  • 仅基于2例病例报告,样本量小,结论的外推性有限。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

CONTEXT: Developmental disorders of the pituitary gland leading to congenital hypopituitarism can either be isolated or associated with extrapituitary abnormalities (syndromic hypopituitarism). A large number of syndromic hypopituitarism cases are linked to mutations in transcription factors. The forkhead box A2 (FOXA2) is a transcription factor that plays a key role in the central nervous system, foregut, and pancreatic development. OBJECTIVE: This work aims to characterize 2 patients with syndromic hypopituitarism due to FOXA2 gene defects. RESULTS: We report a novel heterozygous nonsense c.616C > T(p.Q206X) variant that leads to a truncated protein that lacks part of the DNA-binding domain of FOXA2, resulting in impaired transcriptional activation of the glucose transporter type 2 (GLUT2)-luciferase reporter. The patient is the sixth patient described in the literature with a FOXA2 mutation, and the first patient exhibiting pancreatic hypoplasia. We also report a second patient with a novel de novo 8.53 Mb deletion of 20p11.2 that encompasses FOXA2, who developed diabetes mellitus that responded to sulfonylurea treatment. CONCLUSION: Our 2 cases broaden the molecular and clinical spectrum of FOXA2-related disease, reporting the first nonsense mutation and the first case of pancreatic dysgenesis.

来源:J Clin Endocrinol Metab,查看原文。版权归原作者所有。

引用

  1. Kaygusuz SB, Arslan Ates E, Vignola ML, et al. Dysgenesis and Dysfunction of the Pancreas and Pituitary Due to FOXA2 Gene Defects. J Clin Endocrinol Metab. 2021. PMID: 33999151. doi:10.1210/clinem/dgab352

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。